StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
Shares of NASDAQ APVO opened at $0.41 on Thursday. Aptevo Therapeutics has a one year low of $0.28 and a one year high of $48.40. The firm’s 50 day simple moving average is $0.56 and its two-hundred day simple moving average is $3.05.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) EPS for the quarter, beating analysts’ consensus estimates of ($14.10) by $4.15. On average, equities analysts anticipate that Aptevo Therapeutics will post -8.86 EPS for the current fiscal year.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- The How and Why of Investing in Gold Stocks
- Why Call Options Volume for These 2 Stocks Spiked Together
- When to Sell a Stock for Profit or Loss
- MarketBeat Week in Review – 7/22 – 7/26
- How to Capture the Benefits of Dividend Increases
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
